Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Having endured an impoverished childhood and bare-bones sickle cell care, Edward ‘Donnell’ Ivy, MD, devotes his career to ...

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction ...

Pain is a constant, complex companion that clinicians often struggle to understand and measure for people living with sickle ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...

Pain is a constant, complex companion that clinicians often struggle to understand and measure for people living with sickle ...

Researchers have found a link between the release from malformed red blood cells of the vital protein that carries oxygen and episodes of severe pain in people with sickle cell disease. The discovery ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...